Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024 18:03 ET | Catalyst Pharmaceuticals, Inc.
    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
tricha shivas (woman)
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
February 15, 2024 06:23 ET | Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024 16:06 ET | Biogen Inc.
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its...
Alterity.png
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
February 06, 2024 07:25 ET | ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...
download.png
Texas Infant to Become Fifth Child to Receive Life-Saving Gene Therapy Treatment on U.S. Soil
February 05, 2024 11:14 ET | The Calliope Joy Foundation
DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Sufyan Pashai, a 4-month-old from Dallas, will travel to Minnesota and become the fifth child to receive life-saving gene therapy treatment on U.S. soil for...
Alterity.png
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
January 29, 2024 07:24 ET | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Global Rare Disease Therapeutics Market
Global Rare Disease Therapeutics Market Outlook, 2028: Hematologic Diseases Propel Market Growth with Novel Treatments, While Injectables Take the Lead in Managing Rare Diseases
January 25, 2024 11:39 ET | Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Rare Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ...
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
January 23, 2024 08:30 ET | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announces that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.